|Application ||WB, IHC-P, FC, E|
|Calculated MW||17700 Da|
|Antigen Region||15-43 aa|
|Other Names||Cyclin-dependent kinase 4 inhibitor D, p19-INK4d, CDKN2D|
|Target/Specificity||This p19 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 15-43 amino acids from the N-terminal region of human p19.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||p19 Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Interacts strongly with CDK4 and CDK6 and inhibits them.|
|Cellular Location||Nucleus. Cytoplasm|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
p19 is a member of the INK4 family of cyclin-dependent kinase inhibitors. This protein has been shown to form a stable complex with CDK4 or CDK6, and prevent the activation of the CDK kinases, thus function as a cell growth regulator that controls cell cycle G1 progression. The abundance of the transcript of this gene was found to oscillate in a cell-cycle dependent manner with the lowest expression at mid G1 and a maximal expression during S phase. The negative regulation of the cell cycle involved in this protein was shown to participate in repressing neuronal proliferation, as well as spermatogenesis.
Cunningham, J.M., et al. Br. J. Cancer 101(8):1461-1468(2009)
Zhang, W., et al. Acta Biochim. Biophys. Sin. (Shanghai) 41(5):414-428(2009)
Agarwal, S.K., et al. J. Clin. Endocrinol. Metab. 94(5):1826-1834(2009)
Goode, E.L., et al. Cancer Epidemiol. Biomarkers Prev. 18(3):935-944(2009)
Mavaddat, N., et al. Cancer Epidemiol. Biomarkers Prev. 18(1):255-259(2009)
If you have any additional inquiries please email technical services at firstname.lastname@example.org.